Daewoong Pharmaceutical Co Ltd (Daewoong Pharmaceutical), a subsidiary of Daewoong Co Ltd, focuses on the research, development, manufacturing and commercialization of pharmaceuticals. The company offers a broad portfolio of prescription drugs and non-prescription products for various conditions including bone and joint diseases, cardiovascular diseases, central nervous system diseases, diabetes, circulatory system, dermatological, gastrointestinal, health supplements and respiratory remedies, among others.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Daewoong Pharmaceutical conducts R&D to discover new drugs, biologics and new products for cancer, immune diseases, stem cell therapy for intractable and rare diseases, and vaccines. The company aims to achieve this through the launch of major products through open collaboration and an extensive R&D portfolio. Its key initiatives include the expansion of sales countries for Pecsuklu, the release and extension of Enblo, and strengthening the portfolio of treatments for autoimmune, fibrotic, metabolic, and cancer diseases. The company is also expanding new modalities such as TPD, developing stem cell treatments for intractable diseases, and expanding Nabota treatment indications. It also in-licenses various products from other companies and develops them. Additionally, Daewoong Pharmaceutical is working on the development of bio-convergence medical devices, new substances related to aging, and proprietary pharmaceutical products for global expansion. The company is also focusing on cell and gene therapy, expanding the pipeline for anticancer, metabolic, immune diseases, and vaccine R&D, and developing first-in-class protein drugs. The R&D unit of Daewoong Pharmaceutical is responsible for the development of new drugs that benefit patients, strengthening global leadership in autoimmune, fibrotic, metabolic, and cancer treatments, and securing sustainable new drug asset discovery capabilities. It is also involved in next-generation biopharmaceutical development, including smart stem cell therapy, cell and gene therapy, and exosome therapeutic business development. Additionally, it focuses on developing improved new drugs based on innovative platform technology, expanding the nasal spray pipeline, and securing new pipelines through collaboration and development (C&D). In FY2024, the company spent KRW171,289.6 million on its R&D activities, which as a percentage of revenue stood at 12%.